戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 sion, indicating the compound functions as a radiosensitizer.
2 idate for further development as a potential radiosensitizer.
3  cancer demonstrating the role of RK-33 as a radiosensitizer.
4        Our studies identify MMAE as a potent radiosensitizer.
5  now shows promise as an anticancer drug and radiosensitizer.
6 super-repressor constructs) to function as a radiosensitizer.
7 ile, either as a chemotherapeutic agent or a radiosensitizer.
8 eta-lap may warrant clinical evaluation as a radiosensitizer.
9 eatment of pancreatic cancer and is a potent radiosensitizer.
10 d who have not received prior cisplatin as a radiosensitizer.
11 sistance, and the EGFR KI GW572016 acts as a radiosensitizer.
12 of the head and neck (SCCHN) and an in vitro radiosensitizer.
13 ting that 6-aminonicotinamide is acting as a radiosensitizer.
14 y and the potential use of ATM inhibitors as radiosensitizers.
15 anism of Cu-Cy for cancer treatment as a new radiosensitizers.
16 mall peptides as specific ATM inhibitors and radiosensitizers.
17 all molecules that could function as thermal radiosensitizers.
18 d docetaxel are being extensively studied as radiosensitizers.
19                          However, using both radiosensitizers, a significantly greater radiosensitiza
20 tter understand the interaction of these two radiosensitizers, additional studies on DNA repair and c
21 b should be considered a potential cutaneous radiosensitizer and an inducer of radiation recall derma
22 rected conjugate, could function as a potent radiosensitizer and be selectively delivered to tumors u
23 tive component of soy isoflavones, acts as a radiosensitizer and potentiates prostate tumor cell kill
24             NP Wtmn was found to be a potent radiosensitizer and was significantly more effective tha
25 articles (NPs) are studied as drug carriers, radiosensitizers and imaging agents, and characterizing
26 iation regimens, the use of new hypoxic cell radiosensitizers and monoclonal antibodies that inhibit
27                             As a new type of radiosensitizers and photosensitizers, Cu-Cy nanoparticl
28 hroughput screening method to identify novel radiosensitizers and suggest that NS-123 and similar nit
29 perimental data show that glucoazomycins are radiosensitizers and that they competitively inhibit glu
30 ted therapeutic compounds, NU7441 - a potent radiosensitizer, and gemcitabine - an FDA approved chemo
31 plore combinations of FU with cisplatin, new radiosensitizers, and active drugs combined with RT to r
32 e have demonstrated that POH is an effective radiosensitizer at clinically relevant doses of radiatio
33 ere selected as candidate Notch-1-regulating radiosensitizers based on the results of assay screening
34 w a significant increase in the ratio of the radiosensitizer bromodeoxyuridine (BUdR) in tumors versu
35 Here we show that hyperthermia, an effective radiosensitizer, can induce several steps associated wit
36       The hetero-bifunctional nitroimidazole radiosensitizer CI-1010, R-alpha-[[(2-bromoethyl)-amino]
37 cantly more effective than the commonly used radiosensitizer cisplatin in vitro in three cancer cell
38 iosensitization using antibodies to restrict radiosensitizer delivery.
39 nly on physical improvements in delivery, as radiosensitizer development to target tumor cells has ye
40 ) complex may thus be a potential target for radiosensitizer development.
41 easibility of administering carboplatin as a radiosensitizer during craniospinal radiation therapy (C
42  These data support testing of curcumin as a radiosensitizer for the clinical treatment of alveolar r
43 ncept for use of MLN4924 as a novel class of radiosensitizer for the treatment of pancreatic cancer.
44  larger than that of the most popularly used radiosensitizers, gold nanoparticles (1.19), and paclita
45  particular, the use of biological agents as radiosensitizers has led to the investigation of new com
46 t clear yet and Cu-Cy nanoparticles as novel radiosensitizers have never been tested on colorectal ca
47          Nitric oxide (NO) is a potent tumor radiosensitizer; however, its clinical use is limited by
48 ext, we have addressed new avenues including radiosensitizers, hypoxia, metabolism, angiogenesis, inv
49        Furthermore, MLN4924 was an effective radiosensitizer in a mouse xenograft model of human panc
50                   CRLX101 was evaluated as a radiosensitizer in colorectal cancer cell lines and muri
51 ognized as an effective in vitro and in vivo radiosensitizer in human cancers.
52 ti-alphav integrin monoclonal antibody, is a radiosensitizer in mice with xenograft tumors.
53 oRNA (miR)-24 acts as a tumor suppressor and radiosensitizer in NPC cells and xenografts by targeting
54 nce that MLN4924 can be used as an effective radiosensitizer in pancreatic cancer.
55  carcinoma, we evaluated 2ME2 as a potential radiosensitizer in prostate cancer models.
56 nical utilization of beta-lap (Arq 501) as a radiosensitizer in prostate cancers that overexpress NQO
57 proved drug, nelfinavir, may be an effective radiosensitizer in the clinic.
58 ical utility of pharmacologic ascorbate as a radiosensitizer in the treatment of pancreatic cancer.
59 alternative to intravenous fluorouracil as a radiosensitizer in these patients.
60 idine; dFdCyd) has been shown to be a potent radiosensitizer in tumor cells both in vitro and in vivo
61 f NP Wtmn, we evaluated the therapeutic as a radiosensitizer in vitro and in vivo.
62 one (beta-lap; Arq 501), can act as a potent radiosensitizer in vitro through an unknown mechanism.
63 inally, NP Wtmn was shown to be an effective radiosensitizer in vivo using two murine xenograft model
64 tial development of topoisomerase I drugs as radiosensitizers in treating human malignancies.
65  Caffeine and okadaic acid, both established radiosensitizers, inhibit the incorporation of BrdU in G
66                  The use of carboplatin as a radiosensitizer is a promising strategy for patients wit
67 diation that can serve as a highly effective radiosensitizer is reported here, significantly sensitiz
68               Heat is one of the most potent radiosensitizers known.
69                           The antimetabolite radiosensitizers may inhibit thymidylate synthase (TS) o
70 4'-bromo-3'-nitropropiophenone (NS-123) as a radiosensitizer of human glioma cells in vitro and in vi
71  combination with radiation was an effective radiosensitizer of murine NIH-3T3 fibroblasts, with a se
72                     Nitric oxide is a potent radiosensitizer of tumors, but its use clinically is lim
73 on inhibitors may prove clinically useful as radiosensitizers of tumors that depend on ras function.
74 ancer cells and evaluated its potential as a radiosensitizer on cell lines and prostate tumor xenogra
75 iodiagnostics, but they are not effective as radiosensitizers/radiochemotherapeutics.
76 inase inhibitors may be more potent cellular radiosensitizers than ATM kinase inhibitors, and that th
77 (Cu-Cy) is a new photosensitizer and a novel radiosensitizer that can be activated by light, X-ray an
78 herapeutic relevance of EphB4 targeting as a radiosensitizer that can be exploited for the treatment
79 ngal metabolite, wortmannin, is an effective radiosensitizer that irreversibly inhibits certain membe
80        PS-341 is a potent, selective in vivo radiosensitizer that may substantially affect the effica
81 rhamnetin and cirsiliol can act as promising radiosensitizers that enhance the radiotherapeutic effic
82                      Adding gemcitabine as a radiosensitizer to 9.25 MBq of PT-RAIT enhanced objectiv
83            Biologically, PD0166285 acts as a radiosensitizer to sensitize cells to radiation-induced
84 he mechanistic bases for combining these two radiosensitizers to enhance tumor cytotoxicity.
85 ibited potently by the structurally distinct radiosensitizer, UCN-01.
86 assess the interaction of these two types of radiosensitizers, we compared treatment responses to the
87 ne cancer antigen 19-9, and gemcitabine as a radiosensitizer were associated with a major pathologic
88 vel less than 200 U/mL, and gemcitabine as a radiosensitizer were associated with a major response.
89 rapy, but DA was also equally effective as a radiosensitizer when given only 2 hours before fractiona
90 dR) and caffeine are recognized as potential radiosensitizers with different mechanisms of interactio
91  susceptible to a given molecularly targeted radiosensitizer would be of clinical benefit.

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。